Key result
High-dose heparin and r-hirudin reduce LVAD Dacron graft thrombin activity resistant to low-dose heparin.
Why the study?
Patients on LVADs have increased thromboembolism risk and elevated thrombin activity, but the role of thrombin activity on LVAD Dacron grafts and its resistance to anticoagulation was unclear.
LVAD Dacron grafts harbor surface thrombin activity that is resistant to standard anticoagulation, potentially serving as a primary source for LVAD thrombogenicity.
Answers are grounded in this paper and cite their sources.
May explain refractory LVAD thrombosis despite heparin; hypothesis-generating for graft-targeted anticoagulation trials.
Patients on left ventricular assist devices (LVADs) are at increased risk for thromboembolism, and they experience elevations in platelet release and thrombin activity indices during device implantation. The Dacron grafts that lead from the ventricle to the LVAD and back to the aorta may harbor thrombin activity and protect this thrombin from anticoagulant action. To investigate this possibility, specimens isolated from LVAD grafts at the time of device explantation or implantation were incubated with citrated platelet poor plasma (cPPP), cPPP and 2 U/ml of heparin, cPPP and 2 U/ml of recombinant hirudin (r-hirudin), or cPPP and 50 U/ml of heparin. Thrombin activity was measured by the increase in incubated cPPP fibrinopeptide A (FPA) concentrations over cPPP FPA levels, without material contact. A chromogenic substrate for thrombin verified the effects seen. Thrombin activity was found at comparable levels on both the inflow and outflow LVAD grafts at explantation. This activity was not inhibited by low concentrations of heparin, but 50 U/ml of heparin and 2 U/ml of r-hirudin reduced the activity. At graft implantation (after preclotting), thrombin activity was higher than at explantation, but susceptibility to inhibition by heparin was also significantly greater. These results confirm that the LVAD Dacron grafts harbor surface thrombin activity resistant to anticoagulation that may be a primary source for LVAD thrombogenicity.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (1992) studied Left ventricular assist devices (LVADs). LVAD Dacron grafts was evaluated on Thrombin activity measured by fibrinopeptide A (FPA) concentrations. LVAD Dacron grafts harbored surface thrombin activity resistant to low-dose heparin but reduced by 50 U/ml of heparin and 2 U/ml of r-hirudin, suggesting a source for LVAD thrombogenicity.
Synapse has enriched 10 related papers. Consider them for comparative context: